Screener
Relmada Therapeutics, Inc. RLMD Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Other income: | ||
| Interest/investment income, net | 959,762 | 440,287 |
| Realized (loss)/gain on short-term investments | (9,867) | 62,952 |
| Unrealized (loss)/gain on short-term investments | (540,097) | 155,731 |
| Total other income, net | 409,798 | 658,970 |
| Net loss | $(19,051,956) | $(17,559,465) |
| Loss per common share – basic and diluted | $(0.22) | $(0.58) |
| Weighted average number of common shares outstanding – basic and diluted | 86,596,873 | 30,408,890 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s other income (expense)?
- Relmada Therapeutics, Inc. (RLMD) reported other income (expense) of $409.8K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s other income (expense) changed year-over-year?
- Relmada Therapeutics, Inc.'s other income (expense) decreased by 37.8% year-over-year, from $658.97K to $409.8K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s other income (expense)?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s other income (expense) has grown at a 144.1% compound annual growth rate (CAGR), from -$48.32K to $1.72M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Relmada Therapeutics, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude